It is currently Wed Oct 22, 2014 6:49 pm

News News of Ampyra

Site map of Ampyra » Forum : Ampyra

Dalfampridine, or Ampyra, is a potassium channel blocker that is shown to improve visual function, motor skills and relieve fatigue in MS patients.

Ampyra® two-year safety data presented at ECTRIMS

Image

Acorda Therapeutics, Inc. today announced safety data from more than 62,400 people with multiple sclerosis (MS) taking Ampyra (dalfampridine) Extended Release Tablets, 10 mg during the first two years of availability in the United States. The data showed that the safety profile of Ampyra is similar to that observed in clinical trials.

This analysis was presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held ...
Read more : Ampyra® two-year safety data presented at ECTRIMS | Views : 1203 | Replies : 0




Would like to hear from people using Ampyra

Reply to topic in 'general' section:

I have been using it for about 2 months. It's definitely not a wonder drug. I'm really not sure if I am walking any better - maybe marginally. As that research from squiffy stated, I think I would get more or equal benefit from physio.
I think I might go off it for awhile and compare.
When you have a progressive condition like MS, you get in the habit ...
Read more : Would like to hear from people using Ampyra | Views : 2753 | Replies : 14


No added benefit proven for Fampiridine in MS

Image

Drug manufacturer did not present evaluable study data on the appropriate comparator therapy

Fampridine (trade name Fampyra®) has been approved in Germany since July 2011 for adult patients suffering from a higher grade walking disability (grades 4 to 7 on the EDSS disability status scale), as a result of multiple sclerosis (MS). The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed the added benefit of the drug pursuant to the ...
Read more : No added benefit proven for Fampiridine in MS | Views : 2224 | Replies : 5


Acorda's Ampyra fails main goal of post-marketing study

Acorda's Ampyra fails main goal of post-marketing study

Mon Aug 13, 2012 7:39am EDT
(Reuters) - Acorda Therapeutics Inc said a post-marketing study of its multiple sclerosis drug Ampyra failed to meet the main trial goal of an improvement in patients' walking speed.

The 5 mg and 10 mg doses of Ampyra did not yield statistically significant results on the timed 25-foot walk test as compared with the placebo group, the company said.

...
Read more : Acorda's Ampyra fails main goal of post-marketing study | Views : 1335 | Replies : 3


U.S. FDA warns about seizures with MS drug Ampyra

Image

The U.S. Food and Drug Administration has issued a warning to patients and physicians about the increased risk of seizures in multiple sclerosis patients taking the drug Ampyra.

The drug was developed by Acorda Therapeutics Inc to improve walking ability in patients with multiple sclerosis. Biogen Idec Inc has rights to the drug in Europe where it is sold under the brand name Fampyra.

The FDA said that based on reports, it recently evaluated ...
Read more : U.S. FDA warns about seizures with MS drug Ampyra | Views : 1360 | Replies : 0


Ampyra and type of UTI

Antone know the type of UTI Ampyra causes and the preferred antibotic
Read more : Ampyra and type of UTI | Views : 1525 | Replies : 0


Ampyra - 2+ years and working great

My wife has been taking Ampyra for 2+ years now and so far it's working great with her balance and coordination.
No side effects. Was taking it in conjunction with Beta Seron but recently dropped Beta for Gilenya.
Read more : Ampyra - 2+ years and working great | Views : 1583 | Replies : 3


Can you still get compounded 4-AP with Fampyra approved?

Those of you in the USA may know more---are pharmacies allowed to continue co mpounding this. Here in Canada my pharmacist wasn't sure, as Fampyra was just approve. Is it different enough not to be a problem? Are there patent issues? Thanks!
Read more : Can you still get compounded 4-AP with Fampyra approved? | Views : 1705 | Replies : 1


Acorda says MS drug, Ampyra benefits lasted up to 5 years

Image

Acorda Therapeutics Inc. said Wednesday that clinical study data shows its multiple sclerosis drug Ampyra continued to help patients for up to five years.

Ampyra is used to improve the walking speed in MS patients. The company said Wednesday that the benefits of Ampyra that were observed in clinical trials continued for as much as five years in extension studies. The report was based in 483 patients who participated in a late-stage clinical trial ...
Read more : Acorda says MS drug, Ampyra benefits lasted up to 5 years | Views : 1796 | Replies : 0


 

Login  •  Register


Statistics

Total posts 220807 • Total topics 22881 • Total members 14449


Contact us | Terms of Service